API Manufacturers

Analyst Comment

AD/PD 2021: A New Neuro-Regenerative Therapeutic Approach Targeting Protein Kinase C for the Treatment of Alzheimer’s Disease

At the 15th International Virtual Conference on Alzheimer’s disease (AD) and Parkinson’s disease (PD) 2021, a clinical-stage biotech company based in New York, US Synaptogenix, presented its product bryostatin-1 for AD, a novel therapeutic designed to restore cognitive function and regenerate cerebral connections.

GlobalData Healthcare
close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *

Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close